Hsp90 inhibitors: Clinical development and future opportunities in oncology therapy
Tools
Tools
Gao, Zhenhai, Garcia-Echeverria, Carlos and Jensen, Michael Rugaard (2010) Hsp90 inhibitors: Clinical development and future opportunities in oncology therapy. Current Opinion in Drug Discovery and Development, 13 (2). pp. 193-202. ISSN 1367-6733
Abstract
The development of small molecular mass Hsp90 inhibitors has become an increasingly competitive field of research in recent years. Progress in preclinical and clinical research has provided increasing evidence that Hsp90 represents a promising molecular target for the treatment of cancer and other diseases. Although many challenges remain, recent clinical trial results for the most clinically advanced inhibitors indicate that clinical proof of concept in oncology therapy is achievable, and that Hsp90 inhibitors have the potential to contribute to the collection of anticancer treatments available to clinicians and patients in the near future.
| Item Type: | Article |
|---|---|
| Related URLs: | |
| Additional Information: | Author can archive post-print (ie final draft post-refereeing); On a non-profit server |
| Keywords: | Hsp90 inhibitor; anticancer; ATPase; chaperone |
| Related URLs: | |
| Date Deposited: | 13 Oct 2015 13:16 |
| Last Modified: | 13 Oct 2015 13:16 |
| URI: | https://oak.novartis.com/id/eprint/2103 |